Latest / Stock Movers / Nvidia Edges Higher; Sidus Space Rallies; Biohaven Slips on Study
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 3: Time to take a look at some of the stocks
- 0:18Speaker 3: on the move today. We're joined by Bloomberg's Isabelle Lee.
- 0:21Speaker 3: It's a normal trading day today in the New York
- 0:23Speaker 3: Stock Exchange, right.
- 0:24Speaker 1: Absolutely, yes, normal, But the London Stock Market is closed,
- 0:28Speaker 1: so it's very quiet out there for boxing for the
- 0:32Speaker 1: whole world. Yes, boxing day.
- 0:33Speaker 3: Okay, that's quiet.
- 0:34Speaker 1: For the whole world.
- 0:35Speaker 3: Let's start with one of our favorite stocks here because
- 0:39Speaker 3: it's always the most active, in Vidia in the pre market.
- 0:43Speaker 1: In Vidia, Yes, this is a favorite. It's the world's
- 0:46Speaker 1: largest company. It's higher but maybe five one percent in
- 0:52Speaker 1: pre market trading. So they agreed to a licensing deal
- 0:55Speaker 1: with AI startup GROX. So this furthers and vidious investments
- 0:58Speaker 1: and companies connected to the AI boom. So the chip maker,
- 1:02Speaker 1: as we know, has paid for the right to use
- 1:03Speaker 1: GROS technology and will integrate its hip design into future products.
- 1:07Speaker 1: So some of the startups executives are leaving to join
- 1:10Speaker 1: in video to help with that effort. GROK will continue
- 1:12Speaker 1: us an independent company, but they will name a new CEO.
- 1:16Speaker 1: So in Vida's technology, as we know, already dominates data
- 1:18Speaker 1: centers and the popularity of their offerings really has just
- 1:21Speaker 1: made in Video the richest company in the chip industry.
- 1:25Speaker 1: So In Video said it will use some of that
- 1:26Speaker 1: cash to religious advance their uptake of AI across the economy.
- 1:30Speaker 1: So why Grock Because Grock has slow latency chips and
- 1:33Speaker 1: are extremely responsive to inputs. I'm going to pretend that
- 1:37Speaker 1: I really understand it.
- 1:38Speaker 3: Yes, okay, you'll explain that to me some other time.
- 1:42Speaker 3: I've never heard of this company. Is it Citus or
- 1:46Speaker 3: Citus Space?
- 1:48Speaker 1: I thought it was Citus and then I listened to
- 1:49Speaker 1: a video and it said Cidus when the video was
- 1:52Speaker 1: introducing the CEO. So take cars, sid you it's up
- 1:55Speaker 1: eight ten to one percent. This is a space and
- 1:57Speaker 1: defense technology company developments there there recently announced plans to
- 2:02Speaker 1: offer to sell shares if they're common class A common
- 2:06Speaker 1: stock in a proposed public offering at one dollars and
- 2:08Speaker 1: thirty cents a share, So they will use that for
- 2:11Speaker 1: sales and marketing, operational cost, product development, et cetera. Think
- 2:15Speaker 1: equities acting as a sole placement agent for the offering,
- 2:18Speaker 1: and last week the company was named a contract awarding
- 2:21Speaker 1: on the Missile Defense Agency's Shield IDQ program. I also
- 2:26Speaker 1: had to look that up and I got into a
- 2:30Speaker 1: rabbit hole into the Defense Department's website. Basically, that's a
- 2:33Speaker 1: one hundred and fifty one billion dollars sealing contract. Focus
- 2:36Speaker 1: on just really delivering innovative defensive capabilities to efforts that
- 2:43Speaker 1: are militaristic. You could just think of it like that.
- 2:45Speaker 1: So the stock has rallied though, around two hundred percent
- 2:48Speaker 1: in the past month.
- 2:49Speaker 3: All right, let's end up with bio Biohaven shares ticker
- 2:53Speaker 3: symbol bh V, and what do they do.
- 2:57Speaker 1: Bioheavens shares job fourteen percent. They're in the healthcare industry.
- 3:02Speaker 1: So shares are slumping because a mid stage study of
- 3:06Speaker 1: the company's experimental drug for the treatment of major depressive
- 3:10Speaker 1: disorder missed the primary endpoint. So City said that data
- 3:14Speaker 1: was disappointing. They had a by rating, but investors had
- 3:17Speaker 1: quote very low expectations of the study working. Raymond James,
- 3:21Speaker 1: who also had a by rating, said that investors they
- 3:23Speaker 1: focused on the focal epilepsy opportunity and RBC said that
- 3:27Speaker 1: the trial miss could be a clearing event, so to speak.
- 3:30Speaker 1: So the company does not plan on additional psychiat clinical
- 3:34Speaker 1: trials and will, in said, focus on obesity, immunology and
- 3:38Speaker 1: epilepsy in twenty twenty six.
- 3:41Speaker 3: So does everybody want to venture a guess as to
- 3:43Speaker 3: what trading volume is going to be like today? We
- 3:46Speaker 3: should like to put that out there.
- 3:47Speaker 1: There will be ten people on Wall Street.
- 3:50Speaker 2: The stock mover's report from Bloomberg Radio. Check back with
- 3:54Speaker 2: us throughout the day for the latest roundup of companies
- 3:57Speaker 2: making news on Wall Street and for the latest market
- 4:00Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 4:04Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 4:08Speaker 2: the Bloomberg Business app.